Search This Blog

Saturday, January 1, 2022

Texas Clinic Reports 15% Increase in Vasectomies After Near-Total Abortion Ban

 Since Texas enacted its near-total ban on abortion, at least one urologist says business in giving people vasectomies has picked up. Koushik Shaw says he’s seen a 15% increase in men requesting vasectomies since the ban went into effect on September 1. Shaw says his new upswell in patients is definitely because of the ban.

''‘Hey, I’m actually here because some of these changes that [Gov. Greg] Abbott and our legislature have passed that are really impacting our decision-making in terms of family planning,’ so that was a new one for me as a reason — the first time patients are citing state law as their motivating factor,” Shaw said.

So far, Shaw’s is the only clinic that has cited an increase in vasectomy requests, but with the Supreme Court set to decide the fate of Roe vs. Wade in 2022, and with the six-week abortion ban that incentivizes citizens to enforce the law in place until then, more men seem to be considering their role in family planning.

Traditionally, the onus of birth control has been placed on women. Hormonal birth control pills, IUDs, and other forms of birth control are undoubtedly necessary, but many women deal with uncomfortable, and occasionally negative side effects related to birth control use. For families that have already had the children that they want to have, or just don’t want to risk pregnancy, vasectomies are an important way to family plan, especially in states that limit the right to choose.

Earlier this year, Pennsylvania state representative Chris Rabb introduced “parody legislation” with the intent of pointing out the double-standard regarding birth control, family planning, and bodily autonomy. His bill would require men to have a vasectomy after the birth of their third child or their 40th birthday.

“As long as state legislatures continue to restrict the reproductive rights of cis women, trans men, and nonbinary people, there should be laws that address the responsibility of men who impregnate them. Thus, my bill will also codify ‘wrongful conception’ to include when a person has demonstrated negligence toward preventing conception during intercourse,” Rabb wrote in a memo about his proposal.

 Rabb was surprised that his dummy legislation incited ire throughout the nation. 

“The notion a man would have to endure or even think about losing bodily autonomy was met with outrage,” said Rabb. “When every single day women face this and it’s somehow okay for the government to invade the uteruses of women and girls, but it should be off-limits if you propose vasectomies or limit the reproductive rights of men.”

Though many men cringe at the mere mention of the word ‘vasectomy”, the procedure is simple, largely reversible (though reversing a vasectomy is more expensive and a bit more complicated than the initial vasectomy), and brings with it more than a few benefits.

Vasectomies are almost 100% effective at preventing pregnancy, compared to the slightly lower effectiveness of hormonal birth control. Also, vasectomies have few side effects, whereas hormonal birth control can cause negative side effects for some people. Not to mention, vasectomies are one and done—there’s no need to remember to take a pill every day. For people who already have children and are done having kids, vasectomies are the way to go.

Vasectomies are also more inexpensive than birth control. Vasectomies cost on average around $1500 and are generally covered by insurance. In contrast, birth control pills represent an ongoing expense that can average as much as $600 per year. Given that birth control is often taken over the course of someone’s reproductive life, $600 is year is far more expensive than a one-time $1,500 cost. Or tubal ligation, which can cost up to $6000.

https://www.fatherly.com/news/one-texas-clinic-reported-a-15-increase-in-vasectomies-after-near-total-abortion-ban/

Impact of COVID-19 Vaccine Distribution on Mental Health Outcomes

 Virat AgrawalJonathan H. CantorNeeraj Sood & Christopher M. Whaley

DOI 10.3386/w29593

PDF:https://www.nber.org/system/files/working_papers/w29593/w29593.pdf


The COVID-19 pandemic has led to a “second pandemic” of anxiety and depression. While vaccines are primarily aimed at reducing COVID-19 transmission and mortality risks, they may have important secondary benefits. We use data from U.S. Census Bureau’s Household Pulse Survey merged to state-level COVID-19 vaccination eligibility data to estimate the secondary benefits of COVID-19 vaccination on mental health outcomes. To address endogenous COVID-19 vaccination, we leverage state-level variation in the timing of when age groups are eligible for vaccination. We estimate that COVID-19 vaccination reduces anxiety and depression symptoms by nearly 30%. Nearly all the benefits are private benefits, and we find little evidence of spillover effects, that is, increases in community vaccination rates are not associated with improved anxiety or depression symptoms among the unvaccinated. We find that COVID-19 vaccination is associated with larger reductions in anxiety or depression symptoms among individuals with lower education levels, who rent their housing, who are not able to telework, and who have children in their household. The economic benefit of reductions in anxiety and depression are approximately $350 billion. Our results highlight an important, but understudied, secondary benefit of COVID-19 vaccinations.

https://www.nber.org/papers/w29593#fromrss

Nasal spray to prevent COVID infection begins clinical trials

 An innovative clinical trial is set to commence in Australia testing whether a common blood thinning drug can prevent SARS-CoV-2 infection. The drug is administered by nasal spray and researchers believe it can block the virus from initially infecting cells in the nose.

The nasal spray is based on a hypothesis suggesting initial SARS-CoV-2 infections take hold in the nose via a molecule called heparan sulfate. The virus’s infamous spike protein binds to heparan sulfate which enhances its ability to subsequently interact with ACE2 receptors and infect human cells.

Heparin is a widely used anti-coagulant, first discovered over a century ago and safely used as a treatment for heart attacks and blood clots. Gary Anderson, from the University of Melbourne’s Lung Health Research Centre, says early research has indicated heparin is so molecularly similar to heparan sulfate that it can neutralize SARS-CoV-2 particles when administered directly to cells in the nose.

“Heparin – the active ingredient in our spray – has a structure that is very similar to heparan sulphate, so it behaves as a ‘decoy’ and can rapidly wrap around the virus’s spike protein like a python, preventing it from infecting you or spreading the virus to others,” explains Anderson.

The large clinical trial testing the nasal spray will commence soon in the Australian state of Victoria. The plan is to distribute the spray to 400 houses within 24 hours of a confirmed case in each household. The trial will be blinded and placebo controlled, with each participant directed to take two puffs of the spray three times a day.

The goal will be to investigate whether the nasal spray prevents COVID-19 in close contacts of confirmed cases. Active COVID-19 cases will also be given the spray as the researchers are also looking at whether heparin reduces the infectiousness of a confirmed case.

The researchers say administering heparin as a nasal spray should not lead to broader blood thinning as it doesn’t reach the bloodstream when administered through the nose. Anderson also notes this prophylactic nasal spray should be effective against all viral variants.

"Importantly, this nasal spray should prove effective for all COVID-19 variants because the heparan sulphate binding site is essential for infection, and is likely to be preserved in new variants,” says Anderson. “Heparin binds avidly to the Omicron variant currently sweeping through the country.”

The trial is set to run for six months, so it won’t be known how well it works until the second half of 2022. However, if it does prove to be effective, it could be rolled out quickly as the drug is already approved for human use, doesn’t require refrigeration, and is easily distributed in plastic vials.

The treatment is not being proposed as an alternative to vaccination. Instead, the researchers suggest it will hopefully help protect those most vulnerable to severe COVID-19 and prevent onward transmission in those experiencing vaccine-breakthrough infections.

“If the treatment is proven to work in the setting of preventing progression and spread within homes, it would support using the spray to protect highly vulnerable populations such as the elderly, pregnant women, and those with weak immune systems,” says Anderson. “It may also prove useful to protect our front-line health care workers from illness and to preserve capacity in the health care system.”

Source: University of Melbourne

https://newatlas.com/health-wellbeing/nasal-spray-heparin-coronavirus-infection-clinical-trial/

Moderna creates twice as many antibodies as Pfizer, study shows

 Moderna Inc.’s COVID vaccine generated more than double the antibodies of a similar shot made by Pfizer Inc. and BioNTech SE in research directly comparing immune responses to the inoculations.

A study of almost 2,500 workers at a major Belgium hospital system found antibody levels among individuals who hadn’t been infected with the coronavirus before getting two doses of the Moderna vaccine averaged 2,881 units per milliliter, compared with 1,108 units/mL in an equivalent group who got two jabs of the Pfizer shot.

The results, published Monday in a letter to the Journal of the American Medical Association, suggested the differences might be explained by the:

higher amount of active ingredient in the Moderna vaccine -- 100 micrograms, versus 30 micrograms in Pfizer-BioNTech
longer interval between doses of the Moderna vaccine -- four weeks, versus three weeks for Pfizer-BioNTech

Moderna’s vaccine was associated with a two-fold risk reduction against breakthrough SARS-CoV-2 infections compared to Pfizer’s in a review of people in the Mayo Clinic Health System in the U.S. from January to July. The results were reported in a separate study released ahead of publication and peer review on Aug. 9.

https://www.bnnbloomberg.ca/moderna-creates-twice-as-many-antibodies-as-pfizer-study-shows-1.1700253

Buttigieg, FAA chief request delay in 5G rollout over airlines' concerns

 Transportation Secretary Pete Buttigieg and the administrator for the Federal Aviation Administration sent a letter addressed to Verizon and AT&T requesting that they delay their rollout of 5G services amid airlines’ concerns over flight disruptions.

“We ask that your companies continue to pause introducing commercial C-Band service for an additional short period of no more than two weeks beyond the currently scheduled deployment date of January 5,” Buttigieg and FAA Administrator Steve Dickson wrote to the two companies in a letter dated Friday.

The two federal officials said “commercial C-band service would begin as planned in January with certain exceptions around priority airports. The FAA and the aviation industry will identify priority airports where a buffer zone would permit aviation operations to continue safely while the FAA completes its assessments of the interference potential around those airports.”

Buttigieg and Dickson noted that 5G wireless services would be allowed to roll out on a rolling basis around priority airports “such that C-Band planned locations will be activated by the end of March 2022, barring unforeseen technical challenges or new safety concerns.”

The letter noted that the FAA would make assessments as quickly as possible, noting that their goal was to prioritize flight safety.

The letter comes one day after Airlines for America, an airlines trade group, expressed concerns over AT&T’s and Verizon’s 5G rollout, which is expected to start on Jan. 5. Citing a potential for flight disruptions as a result of the 5G rollout's technology, an emergency request was filed to the Federal Communications Commission (FCC) on Thursday.

In November, both cell phone carriers, in an attempt to address regulatory concerns, had made a proposal to limit their 5G services for the first half of 2022.

AT&T and Verizon confirmed to The Hill on Saturday that they had received the letter and were reviewing it.

“Years of research by the government and private industry has proven that 5G and aviation can safely coexist, just as it does in over 40 other nations. There is absolutely no reason why there should or will be any difference in the U.S. Assertions to the contrary are baseless and make absolutely no sense,”  Verizon said in a statement.

https://thehill.com/policy/technology/587860-buttigieg-faa-chief-request-delay-in-5g-rollout-over-airlines-concerns

Michigan shifts, will follow CDC isolation guidance

 The Michigan Department of Health and Human Services (MDHHS) announced on Friday that it would be changing its quarantine guidance to follow recommendations from the Centers for Disease Control and Prevention (CDC), a shift from earlier in the week.

Michigan's state government initially said it would not be following the CDC's new guidelines until it received further information. The new guidance shortened the recommended length of quarantine to five days for asymptomatic individuals regardless of vaccinations status.

The CDC also left out a recommendation to get a negative COVID-19 test before leaving isolation.

On Friday, the MDHHS said in a statement that it would be updating its guidance to "reflect the recent recommendations" from the CDC. 

MDHHS chief medical executive Natasha Bagdasarian said, "We have safe and effective tools for preventing the spread of COVID-19."

"Getting vaccinated continues to be the best protection against severe illness and hospitalization, and we urge all Michiganders over age 5 to get vaccinated as soon as possible," Bagdasarian said.

"These most recent updates to the quarantine and isolation guidelines are a reflection on our progress as we learn more about COVID — but we are not in the clear as variants like omicron continue to create new challenges in the fight to end this pandemic."

The CDC's new recommendations have been criticized by public health experts who warned that the new guidelines may encourage people to leave isolation while still capable of spreading infection. Some experts, like former President Trump's surgeon general Jerome Adams, advised people to still get an antigen test before leaving isolation if possible.

White House chief medical adviser Anthony Fauci defended the updated guidelines, saying this week that they were designed to "balance" the pandemic response.

"The reason is that now that we have such an overwhelming volume of cases coming in, many of which are without symptoms, there's the danger that this is going to have a really negative impact on our ability to really get society to function properly," Fauci said.

https://thehill.com/homenews/state-watch/587826-michigan-updates-guidelines-following-cdc-guidance-after-previous-delay

iTeos Therapeutics Set to Join S&P SmallCap 600

  iTeos Therapeutics Inc. (NASD: ITOS) will replace Magellan Health Inc. (NASD: MGLN) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, January 5. S&P 500 constituent Centene Corp. (NYSE: CNC) is acquiring Magellan Health in a deal expected to be completed soon pending final conditions.

Following is a summary of the changes that will take place prior to the open of trading on the effective date:

Effective Date

Index Name

Action

Company Name

Ticker

GICS Sector

January 5, 2022

S&P SmallCap 600

Addition

iTeos Therapeutics

ITOS

Health Care


S&P SmallCap 600

Deletion

Magellan Health

MGLN

Health Care

For more information about S&P Dow Jones Indices, please visit www.spdji.com

https://finance.yahoo.com/news/iteos-therapeutics-set-join-p-224400392.html